Correction to: Cost‐Effectiveness of Icosapent Ethyl in REDUCE‐IT USA: Results From Patients Randomized in the United States

In the article by William S. Weintraub et al, “Cost‐Effectiveness of Icosapent Ethyl in REDUCE‐IT USA: Results From Patients Randomized in the United States,” which published online December 29, 2023 (J Am Heart Assoc. 2024;13:e032413. DOI: 10.1161/JAHA.123.032413) and was included in January 2, 2024 issue of the journal, corrections were needed.

Because the added cost of icosapent ethyl was overestimated, there were errors in the cost difference between icosapent ethyl and standard care.

The last sentence of the Abstract, which read “At a medication cost of $11.48 per day, the cost per quality‐adjusted life‐year gained was $36 208 in trial and $9582 over the lifetime” has been corrected to read “At a medication cost of $11.48 per day, the cost per quality‐adjusted life‐year gained was $36 208 in trial and $4135 over the lifetime.”

In the Results section, under the heading Lifetime Analysis, the authors stated “Using WAC, IPE increased health care costs over the lifetime by $5078 ($221 403 versus $219 212 [95% CI, $862 decrease to $8482 increase]) and had an ICER of $9582, as shown in the cost‐effectiveness plane and acceptability curves.” This has been changed to “Using WAC, IPE increased health care costs over the lifetime by $2191 ($221 403 versus $219 212 [95% CI, $862 decrease to $8482 increase]) and had an ICER of $4135, as shown in the cost‐effectiveness plane and acceptability curves.”

Within the Table, under the subheading LY results (wholesale acquisition cost), the lifetime cost‐effectiveness results for icosapent ethyl compared with standard care were updated accordingly. Under the subheading QALY results using wholesale acquisition cost, the lifetime cost‐effectiveness results for icosapent ethyl compared with standard care were also updated.

In Figure 2B and 2D, the cost‐effectiveness plane (B) and acceptability curve (D) for wholesale acquisition cost were revised to reflect the corrected cost difference between icosapent ethyl and standard care.

In Figure 4D, the effect of drug cost on the incremental cost‐effectiveness ratio when using wholesale acquisition cost was updated to reflect the corrected daily cost of icosapent ethyl.

In the first paragraph of the Discussion section, the incremental cost‐effectiveness ratio was described as follows: “At $11.48 per day, the ICER was $9582. At a threshold of <$50 000 per QALY gained, IPE was cost‐effective in 99.7% of simulations using net cost and 91.3% WAC costs.” This was corrected to read “At $11.48 per day, the ICER was $4135. At a threshold of <$50 000 per QALY gained, IPE was cost‐effective in 99.7% of simulations using net cost and 93.1% WAC costs.”

The authors regret the errors.

The online version of the article has been updated and is available here: https://www.ahajournals.org/doi/10.1161/JAHA.123.032413

更正：成本效益二十碳五烯酸乙酯美国减少IT：来自美国随机分组的患者的结果

William S. Weintraub 等人于 2023 年 12 月 29 日在线发表的文章“REDUCE-IT USA 中二十碳五烯酸乙酯的成本效益：美国随机患者的结果”（J Am Heart Assoc . 2024;13） ：e032413。DOI：10.1161/JAHA.123.032413）并已包含在 2024 年 1 月 2 日期刊中，需要更正。

由于二十碳五乙酯的附加成本被高估，二十碳五乙酯与标准护理之间的成本差异存在误差。

摘要的最后一句“如果每天的药物费用为 11.48 美元，试验中每个质量调整生命年的成本为 36 208 美元，终生为 9582 美元”，已更正为“以每天的药物费用”每天 11.48 美元，每个质量调整生命年的成本在试验中为 36 208 美元，在整个生命周期中为 4135 美元。”

在结果部分的“终身分析”标题下，作者指出“使用 WAC，IPE 使一生中的医疗保健费用增加了 5078 美元（221 403 美元 vs 219 212 美元[95% CI，减少 862 美元至增加 8482 美元]），并且 ICER 9582 美元，如成本效益平面和可接受性曲线所示。”这已更改为“使用 WAC，IPE 使一生中的医疗保健费用增加了 2191 美元（221 403 美元对比 219 212 美元[95% CI，减少 862 美元至增加 8482 美元]），ICER 为 4135 美元，如成本所示。有效性平面和可接受性曲线。”

在表中，在小标题 LY 结果（批发采购成本）下，与标准护理相比，二十碳五烯乙酯的终生成本效益结果进行了相应更新。在使用批发采购成本的小标题 QALY 结果下，还更新了二十碳五烯酸乙酯与标准护理相比的终生成本效益结果。

在图 2B 和 2D 中，批发采购成本的成本效益平面 (B) 和可接受性曲线 (D) 进行了修改，以反映二十碳五烯酸乙酯和标准护理之间的校正成本差异。

在图 4D 中，更新了使用批发采购成本时药物成本对增量成本效益比的影响，以反映二十碳五烯酸乙酯的校正后的每日成本。

在讨论部分的第一段中，增量成本效益比描述如下：“按每天 11.48 美元计算，ICER 为 9582 美元。在每 QALY 收益低于 50,000 美元的阈值下，IPE 在使用净成本和 91.3% WAC 成本的模拟中具有成本效益，占 99.7%。”已更正为“按每天 11.48 美元计算，ICER 为 4135 美元。在每 QALY 收益低于 50,000 美元的阈值下，使用净成本和 93.1% WAC 成本的 IPE 在 99.7% 的模拟中具有成本效益。”

作者对这些错误表示遗憾。

该文章的在线版本已更新，可在此处获取：https://www.ahajournals.org/doi/10.1161/JAHA.123.032413